Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255645 · ClinicalTrials.gov registry record
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 4,500
- Enrollment target
NCT00255645 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 4,500 participants.
The verdict
NCT00255645 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 4,500 participants
- Enrollment target
Study Summary
This is a long-term safety follow-up study to assess the post-treatment safety, at 12 and 24 months, in patients with type 2 diabetes after participation in the phaseII/III studies GALLANT, GALLEX and ARMOR. In addition, selected patients, including those with pre-defined laboratory or clinical findings, will have a 12-week post-treatment follow-up visit, including laboratory evaluation and adverse event recording.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255645
The ClinicalTrials.gov registry entry for NCT00255645 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00255645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255645 about?
NCT00255645 is a clinical study titled "G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)". This is a long-term safety follow-up study to assess the post-treatment safety, at 12 and 24 months, in patients with type 2 diabetes after participation in the phaseII/III studies GALLANT, GALLEX and ARMOR. In addition, selected patients, including those with pre-defined laboratory or clinical find...
What is the current status of trial NCT00255645?
This trial is currently terminated. The enrollment target is 4,500 participants. The study started on 2005-09. Estimated completion is 2006-12.
Who is sponsoring clinical trial NCT00255645?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.